BACKGROUND: Currently, the acquisition of tissue from metastatic deposits is not recommended as a routine practice. Our aim was to evaluate the discordance rate of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) receptor status between primary tumor and liver metastases and its potential impact on treatment choice. PATIENTS AND METHODS: We retrospectively analyzed a database including 1250 ultrasound-guided liver biopsies carried out at the European Institute of Oncology from August 1999 to March 2009. ER, PgR, and HER2 status were determined by immunohistochemistry and/or FISH. Differences between proportions were evaluated using Fisher's exact test. RESULTS: We identified 255 consecutive patients with matched primary and liver tissue samples. Changes in ER status were observed in 37 of 255 patients (14.5%). Changes in PgR status were observed in 124 of 255 patients (48.6%). Changes in HER2 status were observed in 24 of 172 assessable patients (13.9%). We observed a discordance in receptor status (ER, PgR, and HER2) between primary tumor and liver metastases, which led to change in therapy for 31 of 255 of patients (12.1%). CONCLUSIONS: Biopsy of metastases for reassessment of biological features should be considered in all patients, when safe and easy to carry out, since it is likely to impact treatment choice.
BACKGROUND: Currently, the acquisition of tissue from metastatic deposits is not recommended as a routine practice. Our aim was to evaluate the discordance rate of estrogen receptor (ER), progesterone receptor (PgR), and humanepidermal growth factor receptor 2 (HER2) receptor status between primary tumor and liver metastases and its potential impact on treatment choice. PATIENTS AND METHODS: We retrospectively analyzed a database including 1250 ultrasound-guided liver biopsies carried out at the European Institute of Oncology from August 1999 to March 2009. ER, PgR, and HER2 status were determined by immunohistochemistry and/or FISH. Differences between proportions were evaluated using Fisher's exact test. RESULTS: We identified 255 consecutive patients with matched primary and liver tissue samples. Changes in ER status were observed in 37 of 255 patients (14.5%). Changes in PgR status were observed in 124 of 255 patients (48.6%). Changes in HER2 status were observed in 24 of 172 assessable patients (13.9%). We observed a discordance in receptor status (ER, PgR, and HER2) between primary tumor and liver metastases, which led to change in therapy for 31 of 255 of patients (12.1%). CONCLUSIONS: Biopsy of metastases for reassessment of biological features should be considered in all patients, when safe and easy to carry out, since it is likely to impact treatment choice.
Authors: Armand de Gramont; Sarah Watson; Lee M Ellis; Jordi Rodón; Josep Tabernero; Aimery de Gramont; Stanley R Hamilton Journal: Nat Rev Clin Oncol Date: 2014-11-25 Impact factor: 66.675
Authors: Rinath Jeselsohn; MacIntosh Cornwell; Matthew Pun; Gilles Buchwalter; Mai Nguyen; Clyde Bango; Ying Huang; Yanan Kuang; Cloud Paweletz; Xiaoyong Fu; Agostina Nardone; Carmine De Angelis; Simone Detre; Andrew Dodson; Hisham Mohammed; Jason S Carroll; Michaela Bowden; Prakash Rao; Henry W Long; Fugen Li; Mitchell Dowsett; Rachel Schiff; Myles Brown Journal: Proc Natl Acad Sci U S A Date: 2017-05-15 Impact factor: 11.205
Authors: B Szekely; Zs I Nagy; Zs Farago; O Kiss; G Lotz; K A Kovacs; L Madaras; N Udvarhelyi; M Dank; Gy Szentmartoni; Zs Baranyai; L Harsanyi; A M Tőkés; Jozsef Timar; A M Szasz; J Kulka Journal: Clin Exp Metastasis Date: 2016-11-24 Impact factor: 5.150
Authors: Stefan Aebi; Shari Gelber; Stewart J Anderson; István Láng; André Robidoux; Miguel Martín; Johan W R Nortier; Alexander H G Paterson; Mothaffar F Rimawi; José Manuel Baena Cañada; Beat Thürlimann; Elizabeth Murray; Eleftherios P Mamounas; Charles E Geyer; Karen N Price; Alan S Coates; Richard D Gelber; Priya Rastogi; Norman Wolmark; Irene L Wapnir Journal: Lancet Oncol Date: 2014-01-16 Impact factor: 41.316
Authors: Bryan P Schneider; Robert J Gray; Milan Radovich; Fei Shen; Gail Vance; Lang Li; Guanglong Jiang; Kathy D Miller; Julie R Gralow; Maura N Dickler; Melody A Cobleigh; Edith A Perez; Tamara N Shenkier; Kirsten Vang Nielsen; Sven Müller; Ann Thor; George W Sledge; Joseph A Sparano; Nancy E Davidson; Sunil S Badve Journal: Clin Cancer Res Date: 2013-01-22 Impact factor: 12.531